Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.98
Onconetix, Inc. issued warrants to purchase 4,362,827 shares of Common Stock of warrant to eleven institutional investors for included in aggregate purchase price of approximately $12.9 million.
- Security
- warrant
- Shares
- warrants to purchase 4,362,827 shares of Common Stock
- Purchaser
- eleven institutional investors
- Consideration
- included in aggregate purchase price of approximately $12.9 million
Exact text from the filing
On September 22, 2025, Onconetix, Inc., a Delaware corporation (the “ Company ”), entered into, and sold to eleven institutional investor(s) (collectively, the “ PIPE Investors ”), pursuant to a securities purchase agreement (the “ Securities Purchase Agreement ”) an aggregate of 16,099 shares of Series D convertible preferred stock, par value $0.00001 per share (“ Series D Preferred Stock ”), which are convertible into common stock of the Company, $0.00001 par value per share (the “ Common Stock ”), which includes an issuance of 500 shares of Series D Preferred Stock to a certain investor as consideration for the PIPE Investors’ irrevocable commitment to purchase shares of the Series D Preferred Stock, and warrants to purchase 4,362,827 shares of Common Stock (the “ Warrants ” and, together with the Series D Preferred Stock, the “ PIPE Securities ”), for an aggregate purchase price of approximately $12.9 million.
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.98
Onconetix, Inc. issued 16,099 shares of Series D convertible preferred stock of preferred stock to eleven institutional investors for aggregate purchase price of approximately $12.9 million of which approximately $9.3 million was paid in cash and the balance was used to offset certain amounts.
- Security
- preferred stock
- Shares
- 16,099 shares of Series D convertible preferred stock
- Purchaser
- eleven institutional investors
- Consideration
- aggregate purchase price of approximately $12.9 million of which approximately $9.3 million was paid in cash and the balance was used to offset certain amounts
Exact text from the filing
On September 22, 2025, Onconetix, Inc., a Delaware corporation (the “ Company ”), entered into, and sold to eleven institutional investor(s) (collectively, the “ PIPE Investors ”), pursuant to a securities purchase agreement (the “ Securities Purchase Agreement ”) an aggregate of 16,099 shares of Series D convertible preferred stock, par value $0.00001 per share (“ Series D Preferred Stock ”), which are convertible into common stock of the Company, $0.00001 par value per share (the “ Common Stock ”), which includes an issuance of 500 shares of Series D Preferred Stock to a certain investor as consideration for the PIPE Investors’ irrevocable commitment to purchase shares of the Series D Preferred Stock, and warrants to purchase 4,362,827 shares of Common Stock (the “ Warrants ” and, together with the Series D Preferred Stock, the “ PIPE Securities ”), for an aggregate purchase price of approximately $12.9 million.
View on SEC.gov